Holen Sie sich die Stockscreener-App
7.52
2.87%
0.21
Handel nachbörslich:
7.52
Schlusskurs vom Vortag:
$7.31
Offen:
$7.43
24-Stunden-Volumen:
72,170
Relative Volume:
0.54
Marktkapitalisierung:
$188.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.38M
KGV:
-5.3333
EPS:
-1.41
Netto-Cashflow:
$-15.54M
1W Leistung:
-2.84%
1M Leistung:
-16.26%
6M Leistung:
+39.52%
1J Leistung:
+15.51%
1-Tages-Spanne:
$7.32
$7.59
1-Wochen-Bereich:
$7.25
$8.055
52-Wochen-Spanne:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Firmenname
Nuvectis Pharma Inc
Sektor
Branche
Telefon
360-837-7232
Adresse
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Vergleichen Sie NVCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
7.52 | 188.46M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Maxim Group | Buy |
| 2025-03-17 | Eingeleitet | Laidlaw | Buy |
| 2022-07-13 | Eingeleitet | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In - Seeking Alpha
Insiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchases - Yahoo Finance
Insider Stock Buying Of Nuvectis Pharma Delivers Return On US$2.19m Investment - simplywall.st
Nuvectis Pharma Approves Proposals at Annual Meeting - TipRanks
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Sold by Two Sigma Investments LP - Defense World
Millennium Management LLC Reduces Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
(NVCT) Investment Analysis - news.stocktradersdaily.com
Squarepoint Ops LLC Invests $103,000 in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect? - MSN
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Bought by Northern Trust Corp - Defense World
(NVCT) On The My Stocks Page - news.stocktradersdaily.com
Cubist Systematic Strategies LLC Invests $34,000 in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
When (NVCT) Moves Investors should Listen - news.stocktradersdaily.com
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - GlobeNewswire
Nuvectis pharma investor Charles Mosseri Marlio buys $247k in stock By Investing.com - Investing.com India
Q2 EPS Estimates for Nuvectis Pharma Lifted by HC Wainwright - Defense World
Roth Capital Forecasts Stronger Earnings for Nuvectis Pharma - Defense World
Nuvectis Pharma Launches New $60M Stock Offering Program - TipRanks
Nuvectis Pharma launches public stock offering - MSN
(NVCT) Investment Report - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Nuvectis Pharma Reports Q1 2025 Progress and Financials - TipRanks
Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year - TipRanks
Nuvectis (NVCT) Advances Clinical Programs with Promising Updates | NVCT Stock News - GuruFocus
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Nuvectis Pharma’s (NVCT) “Buy” Rating Reiterated at HC Wainwright - Defense World
Buy Rating for Nuvectis Pharma: Promising Phase 1 Trial Results of NXP900 Highlight Potential in Combination Therapies - TipRanks
Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 - Insider Monkey
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting - The Manila Times
Nuvectis Pharma, Inc. Announces Positive Phase 1a Data for NXP900 Demonstrating Robust Pharmacodynamic Responses and Acceptable Safety Profile - Nasdaq
Breakthrough: Nuvectis NXP900 Cancer Drug Achieves 90% Target Inhibition in Phase 1 Trial - Stock Titan
Nuvectis Pharma (NASDAQ:NVCT) Trading 5.3% Higher – Here’s What Happened - Defense World
(NVCT) Trading Signals - news.stocktradersdaily.com
Is Nuvectis Pharma Inc (NASDAQ: NVCT) A Good Pick For New Investors Now? - Stocksregister
Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN
Nuvectis pharma investor acquires $1.2 million in stock - MSN
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$36m last week; individual investors who hold 48% profited and so did insiders - simplywall.st
SCHD ETF News, 4/14/2025 - The Globe and Mail
Top 5 Small-cap Pharma Stocks in 2025 - Investing News Network
When the Price of (NVCT) Talks, People Listen - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) and Edesa Biotech (NASDAQ:EDSA) Critical Analysis - Defense World
Maxim Group Begins Coverage on Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Maxim Group Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq
Maxim Initiates Nuvectis Pharma at Buy With $17 Price Target - MarketScreener
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference - MarketScreener
CEO ClipsOrvana Minerals: Expanding Gold, Silver & Copper Production Across Key Global Regions - The Globe and Mail
Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire
New Cancer Treatment Breakthrough: NXP900 Data Showcase at Major AACR Conference - Stock Titan
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Sees Large Decline in Short Interest - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Now Covered by Analysts at Laidlaw - Defense World
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvectis Pharma Inc-Aktie (NVCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):